RSS Updates
Email Updates
CombinatoRx (CRXX) is still down in after-hours trading, but nowhere near the levels that it looked like the stock was trading at. The stock was initially down more than 20% after the news came out and before the stock was halted. Shares are actually down only about 3.3% now at $7.05 on what appears to be roughly 415,000 shares. Obviously this is not going to be under that $5.50 year low like this one was looking originally.
The good news, as noted, is that this company is not just a one-trick pony in the molecule land. The bad news is that this failed indication was for Rheumatoid Arthritis and there could have been a great addition in business if this would have worked out. Here is their full research pipeline: 
Sometimes these stock halts create some extra issues on their own, and that is what appears to have happened here on this one.
Jon C. Ogg
March 26, 2007
Buzz up!
Digg
Fark
Facebook
Tip'd
Tweet This
